Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2313 • 2019 ACR/ARP Annual Meeting
Patients with Rheumatoid Arthritis Have a Higher Risk of Bipolar Disorder: A Systematic Review and Meta-analysis
Patompong Ungprasert¹, Nipith Charoenngam ² and Ben Ponvilawan ², ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²Mahidol University, Bangkok, Thailand
Background/Purpose: Patients with chronic autoimmune diseases may have a higher risk of psychiatric illness as a result of chronic neuro-inflammation and immune dysregulation. The current…
Abstract Number: 2331 • 2019 ACR/ARP Annual Meeting
Association of Rheumatoid Arthritis-related Autoantibodies with Pulmonary Function Test Abnormalities in a Prospective Rheumatoid Arthritis Registry
Sicong Huang¹, Xintong He ¹, Tracy J. Doyle ², Alessandra Zaccardelli ¹, Allison Marshall ¹, H. Maura Friedlander ³, Rachel Blaustein ³, Elisabeth Smith ³, Christine Iannaccone ¹, Taysir Mahmoud ³, Michael Weinblatt ¹, Paul Dellaripa ¹, Nancy Shadick ¹ and Jeffrey Sparks ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston
Background/Purpose: Pulmonary involvement in rheumatoid arthritis (RA), such as bronchiectasis, bronchiolitis, pleuritis, or interstitial lung disease (ILD), is associated with high morbidity and mortality. Pulmonary…
Abstract Number: 2355 • 2019 ACR/ARP Annual Meeting
Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis
Thao Nguyen¹, Ingrid Hokstad ², Gia Deyab ³, Tom Eirik Mollnes ⁴, Stefan Agewall ⁴, Morten Fagerland ⁴, Gro Eilertsen ⁵, Mark Feinberg ⁶, Knut Mikkelsen ², Øystein Førre ⁴ and Ivana Hollan ⁷, ¹Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ²Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Oppland, Norway, ³Innlandet Hospital Trust, Bærum, Akershus, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵The Artic University of Norway, Tromsø, Norway, ⁶Harvard Medical School and Brigham and Women´s Hospital, Boston, Boston, MA, ⁷Lillehammer Hospital for Rheumatic Diseases and Brigham and Women’s Hospital, Boston, Lillehammer, Oppland, Norway
Background/Purpose: Inflammation and immune dysregulation appear to significantly contribute to increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA). The complement system is a…
Abstract Number: 2378 • 2019 ACR/ARP Annual Meeting
Comparative Analysis of Clinical, Laboratory and Therapeutic Strategies Among Blacks with Rhupus, SLE and RA
Naureen Kabani¹, Joshy Pathiparampil ², Madina Abduraimova ², Latoya Freeman-Beman ², Sima Terebelo ¹, Abida Hasan ¹, Christon Grant ¹, James Salgado ¹, Manjeet Bhamra ¹, Tracian James-Goulbourne ¹, Khabbab Amin ¹, Yamen Homsi ³ and Isabel McFarlane ², ¹SUNY Downstate Medical Center, Brooklyn, ²SUNY Downstate Medical Center, Brooklyn, NY, ³NYU Langone Medical Center, Brooklyn, NY
Background/Purpose: Rhupus is the overlap of SLE and RA. While a few studies have been conducted among Rhupus patients, no studies have focused on Black…
Abstract Number: 2415 • 2019 ACR/ARP Annual Meeting
Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients
Yash Gandhi¹, Mehmooda Shaikh ², Blisse Vakkalagadda ¹, Grigor Abelian ¹, Neelanjana Ray ¹, Robert Wong ¹ and Bindu Murthy ¹, ¹Bristol-Myers Squibb, Princeton, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Abatacept (ABA) has proven efficacy in autoimmune diseases and is being evaluated in pSS. The purpose of this investigation was to evaluate the pharmacokinetics…
Abstract Number: 2849 • 2019 ACR/ARP Annual Meeting
Radiographic Progression During a 10-Year Follow-Up : Results from the French Cohort ESPOIR
Joanna Kedra¹, David Hajage ², Alexandre Lafourcade ², Bernard Combe ³, Maxime Dougados ⁴ and Bruno Fautrel ⁵, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S1136, Paris France, Paris, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴Cochin Hospital, Paris, France, ⁵Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: In early arthritis, identification of patients at risk of developing joint damage is an important issue. In rheumatoid arthritis (RA), the rate of progression…
Abstract Number: 53 • 2019 ACR/ARP Annual Meeting
Activation of the Desacetylase Sirtuin-1 Counteracts the Activated and Proangiogenic Profile of Endothelial Cells in Rheumatoid Arthritis and Alleviates Experimental Arthritis
Agathe Leblond ¹, Sonia Pezet ¹, Anne Cauvet ¹, Claudine Casas ¹, Julie Pires Da Silva ², Roxane Herve ³, Luca Semerano ⁴, Christophe Lemaire ⁵, Yannick Allanore ⁶ and Jerome Avouac⁶, ¹INSERM U1016, Paris, France, ²Paris Sud University, Chateany Malabry, France, ³Paris 13 University, Bobigny, France, ⁴INSERM UMR 1125 , Université Paris 13, Bobigny, France, ⁵Paris Sud University, Chatenay malabry, France, ⁶Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France
Background/Purpose: To decipher the phenotype of endothelial cells (ECs) derived from circulating progenitors issued from patients with rheumatoid arthritis (RA).Methods: Proliferation capacities between RA and…
Abstract Number: 185 • 2019 ACR/ARP Annual Meeting
Accrual of Multimorbidity After Incident Rheumatoid Arthritis and Matched Comparators Using a Large Prospective Cohort with 30 Years of Follow-up
Kazuki Yoshida¹, Tzu-Chieh Lin ², Melissa Y Wei ³, Susan Malspeis ¹, Su H. Chu ⁴, Carlos Camargo ⁵, Benjamin A. Raby ¹, Hyon K. Choi ⁵, Sara K. Tedeschi ⁶, Medha Barbhaiya ⁷, Bing Lu ¹, Karen Costenbader ¹, Elizabeth Karlson ¹ and Jeffrey Sparks ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Amgen, Thousand Oaks, CA, ³University of Michigan, Ann Arbor, MI, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ⁷Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) patients often suffer from multimorbidity, the coexistence of multiple chronic morbidities. However, little is known about how multimorbidity accrues over time…
Abstract Number: 261 • 2019 ACR/ARP Annual Meeting
Impact of Rheumatoid Arthritis on Outcomes of Atrial Fibrillation: Results for National Inpatient Sample
Shraddha Jatwani¹, Karan Chugh ¹, Bikramjit Bindra ² and Karan Jatwani ³, ¹St. Vincent Evansville, Evansville, ²Government Medical College & Hospital, Chandigarh, India, ³Mount Sinai West - St Luke’s Hospital, New York
Background/Purpose: Atrial Fibrillation (AF) is a common cardiac arrhythmia related to increased cardiovascular morbidity and mortality. There is a significant association of systemic inflammation with…
Abstract Number: 444 • 2019 ACR/ARP Annual Meeting
Criterion Validity of the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) Questionnaire and FLARE-RA Cut-offs for Clinical Decision Making: International Collaboration
Elena Myasoedova¹, Annette De Thurah ², Marie-Line Erpelding ³, Emilce Schneeberger ⁴, Thomas Maribo ⁵, Gustavo Citera ⁶, John Davis ¹, Eric Matteson ⁷, Cynthia Crowson ⁸, Bruno Fautrel ⁹ and Francis Guillemin ³, ¹Mayo Clinic, Rochester, MN, ²Aarhus University Hospital, Aarhus, Denmark, ³Inserm, University of Lorraine, Nancy, France, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵DEFACTUM, Aarhus, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ⁸Mayo Clinic Rochester, Rochester, ⁹Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: Flares are inherent to the rheumatoid arthritis (RA) disease course and associated with poor clinical outcomes including low quality of life, joint damage and…
Abstract Number: 469 • 2019 ACR/ARP Annual Meeting
Location and Size of Affected Joints Are Useful to Predict Prognosis of Patients with Rheumatoid Arthritis
Susumu Nishiyama¹, Tetsuji Sawada ² and Shigeto Tohma ³, ¹Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan, ²Department of Rheumatology, Tokyo Medical University Hospital, Tokyo, Japan, ³National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: To predict prognosis of patients with rheumatoid arthritis (RA) from the location and the size of affected joints.Methods: Data of 7,776 patients with RA,…
Abstract Number: 506 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results
Bernard Combe¹, Alan Kivitz ², Yoshiya Tanaka ³, Désirée van der Heijde ⁴, Franziska Matzkies ⁵, Beatrix Bartok ⁵, Lei Ye ⁵, Ying Guo ⁵, Chantal Tasset ⁶, John Sundy ⁵, Neelufar Mozaffarian ⁵, Robert B.M. Landewé ⁷, Sang-Cheol Bae ⁸, Edward Keystone ⁹ and Peter Nash ¹⁰, ¹CHU Montpellier, Montpellier University, Montpellier, France, ²Altoona Center for Clinical Research, Duncansville, PA, ³University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Amsterdam University Medical Center, Amsterdam, Netherlands, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: Filgotinib (FIL) is an orally administered, potent and selective inhibitor of Janus kinase 1 (JAK1) that has shown good efficacy and was well tolerated…
Abstract Number: 641 • 2019 ACR/ARP Annual Meeting
A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Anders Bengtsson ¹, Helena Tyden ¹, Tiffany Pan ², J. Lee Nelson ³ and Christian Lood², ¹Lund University, Lund, Sweden, ²University of Washington, Seattle, ³Fred Hutchinson Cancer Research Center, Seattle
Background/Purpose: Circulating immune complexes (IC) are detectable in a variety of systemic inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), reflecting the…
Abstract Number: 924 • 2019 ACR/ARP Annual Meeting
Highly-sensitive Cardiac Troponin-I and Beta-2-Glycoprotein-I IgA Antibodies Inform the Utility of Screening and Follow-up Non-invasive Coronary Atherosclerosis Evaluation and Optimize Cardiovascular Risk Assessment in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth ¹, Elizabeth Hernandez ² and Matthew Budoff ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA Medical center and Los Angeles Biomedical Research Institute, Torrance
Background/Purpose: We recently reported that highly-sensitive cardiac troponin-I (hs-cTnI) associates with occult coronary atherosclerosis burden and cardiovascular event (CVE) risk in rheumatoid arthritis (RA). We…
Abstract Number: 1123 • 2019 ACR/ARP Annual Meeting
Healthcare Factors More Predictive of Smoking Cessation in Patients with Rheumatoid Arthritis Than Patient Characteristics
Maria Schletzbaum¹, Xing Wang ¹, Robert Greenlee ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Marshfield Clinic Research Institute, Marshfield, WI
Background/Purpose: Smoking doubles the risk of developing RA, and continuing to smoke after RA diagnosis is associated with worse disease control, treatment failure, and premature…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].